Trials / Terminated
TerminatedNCT01416428
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oprozomib | Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle. |
Timeline
- Start date
- 2011-10-15
- Primary completion
- 2016-08-08
- Completion
- 2019-08-12
- First posted
- 2011-08-15
- Last updated
- 2022-11-08
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01416428. Inclusion in this directory is not an endorsement.